Amneal Pharmaceuticals (AMRX) stock moved after investors reacted to two fresh updates: FDA approval of its romidepsin injection with Competitive Generic Therapy exclusivity, and positive interim Phase 4 data for Parkinson’s treatment CREXONT in the ELEVATE-PD study.

Those approvals and data readouts come on top of steady share price gains, with a 1-year total shareholder return of 80.45% and a very large 3-year total shareholder return, while shorter term share price momentum has been positive rather than explosive.

If you are looking for other healthcare stocks tied to advanced treatment platforms, this could be a good moment to scan the market using our screener for 39 healthcare AI stocks

With Amneal trading at $13.75, showing an intrinsic value estimate at a discount and a price target of $17.20, investors have to ask: is there still upside left here, or is the market already pricing in future growth?

Most Popular Narrative: 20.1% Undervalued

With Amneal shares at $13.75 versus a widely followed fair value of $17.20, the dominant narrative sees meaningful upside still embedded in the story.

Strategic partnerships (such as with Metsera for GLP-1s and ApiJect for U.S. injectables), expansion into high-growth categories (GLP-1s, complex injectables, and biosimilars), and the upcoming launches in international markets (particularly India and Europe) provide new avenues for incremental revenue and profit growth in the coming years.

Want to see what is baked into that valuation gap? The narrative leans on faster earnings, steadier margins, and a richer future earnings multiple than the wider sector.

Result: Fair Value of $17.20 (UNDERVALUED)

However, this depends on effective execution, as pressure in the U.S. generics market and high debt levels could both quickly challenge that upside story.

Another View: Pricing Looks Full On Earnings

The SWS DCF model points to a very large gap between the current $13.75 share price and an estimated future cash flow value of $82.75, suggesting deep undervaluation. However, on a simple P/E basis, Amneal trades at 35.9x, richer than both peers at 18.5x and a fair ratio of 33.5x. This implies less room for error if expectations slip.

Next Steps

Sentiment across these views is mixed, so if this story matters to you, now is a good time to review the key numbers and form your own stance by weighing the 4 key rewards and 3 important warning signs.

Looking for more investment ideas?

If this Amneal story has caught your attention, do not stop here, broaden your watchlist with a few focused stock ideas that fit different goals.

• Target potential upside by scanning a curated set of 49 high quality undervalued stocks that combine attractive pricing with quality fundamentals.
• Strengthen your income focus by reviewing 9 dividend fortresses built around higher-yield stocks with an emphasis on resilience.
• Dial back risk by checking 64 resilient stocks with low risk scores so you are not missing companies that score well on stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.